These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8920706)

  • 41. Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines. US Rotavirus Vaccine Efficacy Group.
    Ward RL; Bernstein DI
    Vaccine; 1995 Sep; 13(13):1226-32. PubMed ID: 8578808
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants.
    Treanor JJ; Clark HF; Pichichero M; Christy C; Gouvea V; Shrager D; Palazzo S; Offit P
    Pediatr Infect Dis J; 1995 Apr; 14(4):301-7. PubMed ID: 7603812
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
    Vesikari T; Clark HF; Offit PA; Dallas MJ; DiStefano DJ; Goveia MG; Ward RL; Schödel F; Karvonen A; Drummond JE; DiNubile MJ; Heaton PM
    Vaccine; 2006 May; 24(22):4821-9. PubMed ID: 16621194
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3.
    Clark HF; Borian FE; Plotkin SA
    J Infect Dis; 1990 Jun; 161(6):1099-104. PubMed ID: 2161038
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccination of Thai infants with rhesus-human reassortant tetravalent oral rotavirus vaccine.
    Simasathien S; Migasena S; Samakoses R; Pitisuttitham P; Sangaroon P; Aree C; Bishop R; Bugg H; Davidson BL; Vesikari T
    Pediatr Infect Dis J; 1994 Jul; 13(7):590-6. PubMed ID: 7970945
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant WI79-9: different dose response patterns to virus surface proteins VP7 and VP4.
    Clark HF; Lawley D; Shrager D; Jean-Guillaume D; Offit PA; Whang SY; Eiden JJ; Bennett PS; Kaplan KM; Shaw AR
    Pediatr Infect Dis J; 2004 Mar; 23(3):206-11. PubMed ID: 15014293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and immunogenicity of tetravalent rhesus-based rotavirus vaccine in Bangladesh.
    Bresee JS; El Arifeen S; Azim T; Chakraborty J; Mounts AW; Podder G; Gentsch JR; Ward RL; Black R; Glass RI; Yunus M
    Pediatr Infect Dis J; 2001 Dec; 20(12):1136-43. PubMed ID: 11740320
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period.
    Armah GE; Kapikian AZ; Vesikari T; Cunliffe N; Jacobson RM; Burlington DB; Ruiz LP
    J Infect Dis; 2013 Aug; 208(3):423-31. PubMed ID: 23599316
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Development of a rotavirus vaccine. Field trials in Venezuela].
    Pérez Schael I; Rojas Mazzei AM; Flores J
    Acta Cient Venez; 1991; 42(6):296-312. PubMed ID: 1668865
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population.
    Santosham M; Letson GW; Wolff M; Reid R; Gahagan S; Adams R; Callahan C; Sack RB; Kapikian AZ
    J Infect Dis; 1991 Mar; 163(3):483-7. PubMed ID: 1995721
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serologic correlates of immunity in a tetravalent reassortant rotavirus vaccine trial. US Rotavirus Vaccine Efficacy Group.
    Ward RL; Knowlton DR; Zito ET; Davidson BL; Rappaport R; Mack ME
    J Infect Dis; 1997 Sep; 176(3):570-7. PubMed ID: 9291301
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rotavirus vaccines against diarrhoeal disease.
    Vesikari T
    Lancet; 1997 Nov; 350(9090):1538-41. PubMed ID: 9388411
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and immunological studies of rotavirus vaccines.
    Vesikari T
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):437-47. PubMed ID: 2851185
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simultaneous administration of rhesus rotavirus vaccine and oral poliovirus vaccine: immunogenicity and reactogenicity.
    Ho MS; Floyd RL; Glass RI; Pallansch MA; Jones B; Hamby B; Woods P; Penaranda ME; Kapikian AZ; Bohan G
    Pediatr Infect Dis J; 1989 Oct; 8(10):692-6. PubMed ID: 2554244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protein-energy malnutrition alters IgA responses to rotavirus vaccination and infection but does not impair vaccine efficacy in mice.
    Maier EA; Weage KJ; Guedes MM; Denson LA; McNeal MM; Bernstein DI; Moore SR
    Vaccine; 2013 Dec; 32(1):48-53. PubMed ID: 24200975
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants.
    Dhingra MS; Kundu R; Gupta M; Kanungo S; Ganguly N; Singh MP; Bhattacharya MK; Ghosh R; Kumar R; Sur D; Chadha SM; Saluja T
    Vaccine; 2014 Aug; 32 Suppl 1():A117-23. PubMed ID: 25091664
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical trials of live oral rotavirus vaccines: the Finnish experience.
    Vesikari T
    Vaccine; 1993; 11(2):255-61. PubMed ID: 8382419
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation.
    Clark HF; Burke CJ; Volkin DB; Offit P; Ward RL; Bresee JS; Dennehy P; Gooch WM; Malacaman E; Matson D; Walter E; Watson B; Krah DL; Dallas MJ; Schödel F; Kaplan kM; Heaton P
    Pediatr Infect Dis J; 2003 Oct; 22(10):914-20. PubMed ID: 14551493
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of two doses of RIT 4237 bovine rotavirus vaccine for prevention of rotavirus diarrhoea.
    Vesikari T; Ruuska T; Delem A; André FE; Beards GM; Flewett TH
    Acta Paediatr Scand; 1991 Feb; 80(2):173-80. PubMed ID: 1852084
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy, immunogenicity and safety of a trivalent live human-lamb reassortant rotavirus vaccine (LLR3) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial.
    Xia S; Du J; Su J; Liu Y; Huang L; Yu Q; Xie Z; Gao J; Xu B; Gao X; Guo T; Liu Y; Zhou X; Yang H
    Vaccine; 2020 Oct; 38(46):7393-7400. PubMed ID: 32451212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.